Clinical trials: Ophthalmic Solutions
Dry Eye Syndromes
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome
- Trial name
- NCT00370747
- Testing
- Ecabet
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Bausch & Lomb Incorporated
Refractive Error, Myopia
Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution
The purpose of this study was to compare lens comfort on Day 30 for Air Optix® lenses cared for with OPTI-FREE® PureMoist® (OFPM) Multi Purpose Disinfecting Solution (MPDS) compared to Acuvue® Oasys® lenses cared for with…
- Conditions
- Refractive Error, Myopia, Hyperopia, Astigmatism
- Trial name
- NCT01809197
- Testing
- Lotrafilcon B contact lenses, Senofilcon A contact lenses, OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)
- Volunteers
- 387 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734197
- Testing
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%
- Where
- 40 sites in United States
- Volunteers
- 349 people
- Sponsor
- Surface Ophthalmics, Inc.
Blepharitis
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.
- Trial name
- DOUBle (NCT01408082)
- Testing
- ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone
- Where
- 45 sites in United States
- Volunteers
- 917 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Healthy
Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers
The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.
- Trial name
- NCT01997879
- Testing
- AR-13324 Ophthalmic Solution, 0.02%
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Aerie Pharmaceuticals
Dry Eye Disease
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or…
- Trial name
- NCT02824913
- Testing
- P-321 Ophthalmic Solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Parion Sciences
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00770133
- Testing
- Ketotifen/naphazoline, Naphazoline, Ketotifen
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT03479307
- Testing
- Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 228 people
- Sponsor
- Faes Farma, S.A.
Acanthamoeba Keratitis
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Prospective randomized study to evaluate the efficacy, safety and tolerability of 0.08% polihexanide (PHMB) eye drops in patients affected by acanthamoeba keratitis.
- Trial name
- NCT03274895
- Testing
- PHMB 0.08%, Propamidine 0.1%, PHMB 0.02%
- Where
- 6 sites in Italy, Poland and 1 more
- Volunteers
- 135 people
- Sponsor
- SIFI SpA
Dry Eye
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.
- Trial name
- NCT00893139
- Testing
- AL-38583 ophthalmic solution 0.05%, AL-38583 ophthalmic solution 0.10%, AL-38583 vehicle
- Volunteers
- 765 people
- Sponsor
- Alcon Research
Refractive Errors, Myopia
Clinical Assessment of a HYDRAGLYDE® Regimen
The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses…
- Conditions
- Refractive Errors, Myopia, Hypermetropia
- Trial name
- NCT03026257
- Testing
- Lotrafilcon B contact lenses with added wetting agent, Samfilcon A contact lenses, POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 323 people
- Sponsor
- Alcon, a Novartis Company
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance
To evaluate the effect of 2 different lubricant eye drops on visual function of patients with dry eye
- Trial name
- NCT00673764
- Testing
- Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension Glaucoma
Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.
To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in terms of efficacy.
- Trial name
- NCT04898387
- Testing
- Bimatoprost Timolol (T4030), Bimatoprost Timolol (Ganfort)
- Where
- Bulgaria
- Volunteers
- 554 people
- Sponsor
- Laboratoires Thea
Keratoconjunctivitis Sicca
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
- Trial name
- NCT00851734
- Testing
- voclosporin ophthalmic solution
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lux Biosciences, Inc.
Refractive Error
Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers
The purpose of this study was to describe mean differences in corneal staining (type and area) for OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS) at Day 30 compared to Baseline (Day 0).
- Trial name
- NCT01484938
- Testing
- OPTI-FREE PureMoist
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution
This is a comparative, open label, parallel group, non interventional study to further demonstrate the efficacy and tolerability of BAT04. In addition the efficacy and safety shall be compared to Hyaluronic acid (HA)-Product.
- Trial name
- NCT01684852
- Testing
- Medical device, drug-like
- Where
- 5 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Bitop AG
Glaucoma, Ocular Hypertension
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
- Trial name
- NCT01123785
- Testing
- INO-8875
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research